Jpmorgan Chase & CO Finch Therapeutics Group, Inc. Transaction History

Jpmorgan Chase & CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.91 - $5.11 $6,780 - $18,140	-3,550 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$5.02 - $10.47 $6,375 - $13,296	-1,270 Reduced 26.35%	3,550 $18,000
Q4 2021 Feb 10, 2022	BUY	$8.95 - $16.88 $1,807 - $3,409	202 Added 4.37%	4,820 $48,000
Q3 2021 Nov 12, 2021	BUY	$12.2 - $16.75 $56,339 - $77,351	4,618 New	4,618 $60,000

Ticker FNCH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,688,400
Market Cap $563M
Description
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides diffi...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.